História Familiar de Diabetes Tipo 2 está Associada com Síndrome Metabólica em Indivíduos Obesos do Sexo Feminino by Rodrigues, Ticiana Costa & Canani, Luis Henrique
ARTIGO ORIGINAL 
 
 
 
 
Serviço de Endocrinologia , Hospital de Clínicas de Porto Alegre, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre. 
Correspondence Ticiana C. Rodrigues Serviço de Endocrinologia do Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 2350, Prédio 12. 
CEP: 90035-903, Porto Alegre, RS, Brasil. E-mail: tcostarodrigues@terra.com.br Phone: + 55 51 21018127  Fax: + 55 51 2101 8777. 
FAMILY HISTORY OF TYPE 2 DIABETES IS ASSOCIATED WITH  
METABOLIC SYNDROME IN OBESE FEMALE SUBJECTS 
 
HISTÓRIA FAMILIAR DE DIABETES TIPO 2 ESTÁ ASSOCIADA COM  
SÍNDROME METABÓLICA EM INDIVÍDUOS OBESOS DO SEXO FEMININO 
 
Ticiana Costa Rodrigues, Luis Henrique Canani 
 
ABSTRACT 
 
The aim of this study was to evaluate the association between the family history (FH) of type 2 diabetes and 
metabolic syndrome (MetS) in a group of non-diabetic obese female subjects. A cross-sectional study was conducted in 
239 female patients with obesity, regularly attending the Internal Medicine Division’s outpatient clinic (Hospital de Clíni-
cas de Porto Alegre, Brazil). The inclusion criteria were patients with body mass index ≥30 kg/m2 and absence of type 2 
diabetes. The FH was considered positive if a first degree relative had a diagnosis of diabetes. Seventy-four of 239 pa-
tients evaluated (30%) had a positive FH for type 2 diabetes. Patients with positive FH had higher waist/hip ratio and 
MetS more often than patients with negative FH. FH of type 2 diabetes was associated with MetS in this sample of non-
diabetic obese female patients. Waist/hip ratio and fasting plasma glucose, markers of insulin resistance, were also as-
sociated with FH of type 2 diabetes. The simple question: “Do you have a FH of type 2 diabetes?” may help to identify 
the obese patients that should be better evaluated and intensively treated with the objective of preventing type 2 diabe-
tes. 
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RESUMO 
 
O objetivo deste estudo foi avaliar a associação entre história familiar (HF) de diabetes melito tipo 2 (DM2) e sín-
drome metabólica (SM) em um grupo de mulheres obesas não-diabéticas. Conduzimos um estudo transversal com 239 
mulheres com obesidade, regularmente atendidas no ambulatório de medicina interrna do Hospital de Clínicas de Porto 
Alegre, Brasil. Os critérios de inclusão foram pacientes com índice de massa corporal ≥30 kg/m2 e ausência de DM2. A 
HF de DM2 foi considerada positiva se um familiar de primeiro grau tivesse o diagnóstico de diabetes. Setenta e quatro 
das 239 pacientes avaliadas (30%) tiveram uma HF positiva de DM2. Pacientes com HF positiva tiveram maior razão 
cintura/quadril e mais frequentemente a presença de SM que as pacientes com HF negativa. A HF de DM2 foi associa-
da com SM nesta amostra de pacientes femininas obesas não-diabéticas.  A razão cintura/quadril e a glicemia de jejum, 
ambos marcadores de resistência à ação da insulina, foram também associadas com HF de DM2. A simples pergunta: 
“Você tem uma HF de DM2”? pode ajudar a identificar pacientes obesos que devem ser mais bem avaliados e intensa-
mente tratados com o objetivo de prevenção do DM2. 
Unitermos: Obesidade, síndrome metabólica, história familiar, diabetes melito tpo 2.  
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The recent epidemic of obesity has been ac-
companied by an increased incidence of type 2 diabe-
tes (1). In Brazil, obesity and overweight are present 
in 9.7 and 28.3% of the adults, respectively (2). The 
higher frequency is seen among women, affecting 
50% of women between 50 and 69 years old (2). Obe-
sity and family history (FH) of type 2 diabetes are 
important predictors of type 2 diabetes (3). Subjects 
with FH of type 2 diabetes are more insulin resistant 
and/or have decreased insulin secretion compared to 
those without FH of diabetes (4). FH of type 2 diabe-
tes is also associated with metabolic syndrome 
(MetS), abdominal obesity and hyperglycemia (5). 
MetS is an important cluster of cardiovascular disease 
(CVD) risk factors that contribute to insulin resis-
tance.  
The aim of this report was to evaluate the asso-
ciation between the FH of type 2 diabetes and MetS in 
a group of non-diabetic obese female subjects.  
 
METHODS 
 
A cross-sectional study was conducted in 239 
female patients with obesity, regularly attending the 
Occupational Medicine Division’s outpatient clinic at 
Hospital de Clínicas de Porto Alegre. The inclusion 
criteria were patients with body mass index (BMI) 
≥30 kg/m2, absence of type 2 diabetes [established by 
clinical history, normal fasting glycemia (≤125 mg/dl) 
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and a 2-h oral glucose tolerance test with 75 g glucose 
< 200 mg/dl] (6). The FH was considered positive if a 
first degree relative had a diagnosis of diabetes. The 
Ethics Committee of the hospital approved the pro-
ject, and written informed consent was obtained from 
all patients.  
Patients underwent an interview and clinical 
examination to record demographic and anthropomet-
ric data. Blood pressure evaluations were performed 
with the patients in regular use of their medications 
(including antihypertensive medications). The mean 
of two office blood pressure measurements (left arm 
and with the patient in a sitting position, after a 10-
min rest) were considered for the analysis.  
The presence of MetS was determined accord-
ing to 3 criteria. The World Health Organization 
(WHO) criterion requires the presence of two or more 
of the following, besides diabetes: hypertension 
(blood pressure ≥140/90 mm Hg and/or anti-
hypertensive treatment), triglycerides ≥150 mg/dl, 
HDL <35 mg/dl in men and <39 mg/dl in women, 
obesity (body mass index >30 kg/m2 and/or waist-hip 
ratio >0.90 in males and >0.85 in females), presence 
of albuminuria (micro or macroalbuminuria) (7). Na-
tional Cholesterol Education Program (NCEP) Adult 
Treatment Panel III (ATP III), as modified by the 
American Heart Association (AHA)/National Heart, 
Lung, and Blood Institute (8), requires that the pa-
tients have three or more: waist circumference ≥102 
cm in men and ≥88 cm in women, triglycerides ≥150 
mg/dl, HDL <40 mg/dl in men and <50 mg/dl in 
women, blood pressure ≥135/85 mm Hg or use of an-
tihypertensive drugs and fasting glucose ≥100 mg/dl. 
International Diabetes Federation (IDF) requires that 
the patients have waist circumference >94 cm for men 
and >80 cm for women and two or more of the fol-
lowing were present: triglyceride level ≥150 mg/dl, 
HDL cholesterol <40 mg/dl if men or <50 mg/dl if 
women, blood pressure >130/85 mm Hg or taking an-
tihypertensive medication, and fasting glucose >100 
mg/dl (9). 
Plasma glucose was measured by the glucose-
peroxidase colorimetric enzymatic method (Biodiag-
nostica). Creatinine was measured by the Jaffé method 
and the lipid profile by colorimetric methods. The 
glomerular filtration rate (GFR) was estimated using 
the formula of the Modification of Diet in Renal Dis-
ease Study (10): 186 x [serum creatinine -1.154 x age-
0.203 x (0.742, if female) x (1.210, if of African de-
scendant)].  
Student’s T test was used for continuous vari-
ables and the P2 test was used for categorical vari-
ables. Data were expressed as mean ± S.D., except for  
triglycerides, that were log-transformed for analysis 
and expressed as median and range. A P <0.05 was 
considered to be significant. 
 
RESULTS 
 
Seventy-four of 239 patients evaluated (30%) 
had a positive FH for type 2 diabetes. Clinical and 
laboratory data according to the presence or absence 
of diabetes FH are described in Table 1. Patients with 
positive FH had a higher waist/hip ratio and MetS 
more often than patients with negative FH. There 
were no differences regarding age, BMI, blood pres-
sure levels, and ethnic distribution between groups. 
Regarding laboratory values, the only difference 
found was higher fasting plasma glucose among those 
with positive FH compared to those with negative FH. 
The lipid profile as well as the GFR were not different 
between patients with and without diabetes FH.  
 
Table 1: Descriptive data for patients with and with-
out family history of type 2 diabetes. 
 
 Family History of Diabetes  
 Positive 
N (74) 
Negative 
N (165) 
 
P 
Age (years) 39.8 ± 7.2 39.2 ± 8.7 0.590 
Ethnicity (white) n (%) 41 (55.4) 111 (67.5) 0.080 
BMI (kg/m2) 34.4 ± 3.5 35.0 ± 3.8 0.240 
Waist circumference (cm) 102  ±  9 100 ± 9 0.10 
Systolic blood pressure 
(mmHg) 
126.1 ± 17 122.7 ± 13 0.11 
Diastolic blood pressure 
(mmHg) 
80.6 ± 10 79.6 ± 9.7 0.49 
Hypertension n (%) 25 (33.8) 44 (27) 0.29 
Total cholesterol (mg/dl) 198 ± 42 193 ± 38 0.43 
HDL cholesterol (mg/dl) 51 ± 12 53 ± 13 0.39 
LDL cholesterol (mg/dl) 121 ± 35 117 ± 33 0.47 
Triglycerides (mg/dl) 177 (67-521) 97 (43–303) 0.07 
Fasting glucose (mg/dl) 97 ± 9 93 ± 9 0.04 
GFR 
(ml/min per 1.73m2) 
95 ± 17 95 ± 30 0.89 
MetS WHO n (%) 25 (34) 32 (19.6) 0.03 
MetS NCEP n (%) 32 (44) 41 (24.7) 0.006 
MetS IDF n (%) 34 (45.8) 44 (27) 0.009 
Data are means ± SD, median (range) or %. BMI= body mass 
index, GFR= glomerular filtration rate, WHO= World Health 
Organization, NCEP= National Cholesterol Education Pro-
gram, IDF= International Diabetes Federation, MetS= meta-
bolic syndrome. 
Family history of type 2 diabetes in female obese 
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DISCUSSION 
 
FH of type 2 diabetes was associated with MetS 
in this sample of non-diabetic obese female patients, 
independently of the definition used. Waist/hip ratio 
and fasting plasma glucose, both markers of insulin 
resistance, were also associated with FH of type 2 
diabetes.  
The association between FH and risk for diabe-
tes has been previously demonstrated (11,12). The 
presence of MetS has been considered a risk factor for 
CVD and early mortality in non diabetic subjects 
(13,14). MetS is also an important risk factor for de-
veloping type 2 diabetes and is present in more than 
80% of these patients (15). Patients with diabetes and 
MetS are at greater risk, not only for macrovascular 
disease but also for microvascular complications (15). 
All subjects included in the present study were 
obese. Obesity is a well known risk factor for CVD, 
diabetes and MetS. Probably for this reason, there was 
a high prevalence of FH of diabetes (30%). 
This is the first report showing the association 
between FH of type 2 diabetes and MetS in Brazilian 
obese women. A possible limitation of the present 
study is the use of self-report for parental diabetes 
status. This is prone to bias due to unknown diabetes 
among parents. Even with this potential underreport, 
positive FH of diabetes was associated with MetS.  
Recently, a study in the American population 
confirmed the FH of diabetes is independently associ-
ated with diabetes and suggests the possibility of add-
ing FH to public health strategies to detect and pre-
vent diabetes (16). This idea is very interesting, espe-
cially in developing countries. FH is easy to obtain 
and conveniently conveys information on genes and 
environment shared by close relatives (17). The cost-
effectiveness of adding FH to the health programs of 
patients with obesity needs be evaluated. The simple 
question: “Do you have a FH of type 2 diabetes?” 
may help to identify the obese patients that should be 
better evaluated and intensively treated for the pur-
pose of preventing type 2 diabetes. 
The association between MetS and positive FH 
of diabetes in obese patients probably increases or 
anticipates the risk for diabetes and CVD, but this still 
needs to be evaluated and proved. Therefore, so far, 
the presence of FH of diabetes in obese patients 
should be evaluated independently of presence of 
MetS.       
In summary, obese women with positive FH for 
diabetes more frequently have MetS. The simple in-
clusion and valorization of this information in the rou-
tine evaluation of obese subjects might help decrease 
the burden of diabetes and its consequences.  
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